syringaresinol has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, J; Cui, J; Feng, L; Gao, Y; Li, G; Li, J; Liu, C; Liu, J; Pan, Z; Qi, Z; Wang, Y; Xu, Y; Yan, J; Yang, L; Zhang, S | 1 |
| An, J; Feng, L; Gao, Y; Li, D; Li, G; Li, J; Li, Y; Liu, J; Qi, Z; Xu, Y; Yang, J; Yang, L | 1 |
2 other study(ies) available for syringaresinol and Alloxan Diabetes
| Article | Year |
|---|---|
Syringaresinol protects against diabetic nephropathy by inhibiting pyroptosis via NRF2-mediated antioxidant pathway.
Topics: Animals; Antioxidants; Caspases; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Mice; NF-E2-Related Factor 2; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis | 2023 |
Syringaresinol Protects against Type 1 Diabetic Cardiomyopathy by Alleviating Inflammation Responses, Cardiac Fibrosis, and Oxidative Stress.
Topics: Animals; Apoptosis; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Fibrosis; Furans; Hyperglycemia; Kelch-Like ECH-Associated Protein 1; Lignans; Male; Mice, Inbred C57BL; Myocarditis; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidative Stress | 2020 |